Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide Challenge Test for Early Detection of Alzheimer's Disease
NCT03560960Phase 1Active, not recruiting
- Sponsor
- Boston University
- Start
- Feb 2020
- Primary completion
- Nov 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pramlintide in Alzheimer's disease (AD) (3 arms), sponsored by Boston University. Primary endpoints: Plasma Amyloid-beta 1-40 levels, Plasma Amyloid-beta 1-42 levels and 1 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
pramlintide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03560960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560960.